Indication
For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and, if RAS wildtype and medically appropriate, an anti-EGFR therapy
Medicine details
- Medicine name:
- fruquintinib (Fruzaqla)
- SMC ID:
- SMC2858
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Publication due date:
- 13 October 2025
- SMC meeting date:
- 02 September 2025
- Patient group submission deadline:
- TBC